Karan Dixit1, Priya Kumthekar2. 1. Department of Neurology, Division of Neuro-Oncology, Northwestern University, 710 N. Lake Shore Dr., Abbott Hall Room 1123, Chicago, IL, 60611, USA. karan.dixit@northwestern.edu. 2. Department of Neurology, Division of Neuro-Oncology, Northwestern University, 710 N. Lake Shore Dr., Abbott Hall Room 1123, Chicago, IL, 60611, USA.
Abstract
PURPOSE OF REVIEW: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with a dismal prognosis despite aggressive multimodal management thus novel treatments are urgently needed. Gene therapy is a versatile treatment strategy being investigated in multiple cancers including GBM. In gene therapy, a variety of vectors or "carriers" are used to deliver genes designed for different anti-tumoral effects. Gene delivery vehicles and approaches to treatment will be addressed in this review. RECENT FINDINGS: The most commonly studied vectors are viral based, however, driven by advances in biomedical engineering, mesenchymal and neural stem cells, as well as multiple different types of nanoparticles have been developed to improve tumor tropism and also increase gene transfer into tumor cells. Different genes have been studied including suicide genes, which convert non-toxic prodrug into cytotoxic drug; immunomodulatory genes, which stimulate the immune system; and tumor suppressor genes which repair the defect that allow cells to divide unchecked. Gene therapy may be a promising treatment strategy in neuro-oncology as it is versatile and flexible due to the ability to tailor vectors and genes for specific therapeutic activity. Pre-clinical studies and clinical trials have demonstrated feasibility and safety of gene therapy; however, further studies are required to determine efficacy.
PURPOSE OF REVIEW: Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with a dismal prognosis despite aggressive multimodal management thus novel treatments are urgently needed. Gene therapy is a versatile treatment strategy being investigated in multiple cancers including GBM. In gene therapy, a variety of vectors or "carriers" are used to deliver genes designed for different anti-tumoral effects. Gene delivery vehicles and approaches to treatment will be addressed in this review. RECENT FINDINGS: The most commonly studied vectors are viral based, however, driven by advances in biomedical engineering, mesenchymal and neural stem cells, as well as multiple different types of nanoparticles have been developed to improve tumor tropism and also increase gene transfer into tumor cells. Different genes have been studied including suicide genes, which convert non-toxic prodrug into cytotoxic drug; immunomodulatory genes, which stimulate the immune system; and tumor suppressor genes which repair the defect that allow cells to divide unchecked. Gene therapy may be a promising treatment strategy in neuro-oncology as it is versatile and flexible due to the ability to tailor vectors and genes for specific therapeutic activity. Pre-clinical studies and clinical trials have demonstrated feasibility and safety of gene therapy; however, further studies are required to determine efficacy.
Authors: S Harrow; V Papanastassiou; J Harland; R Mabbs; R Petty; M Fraser; D Hadley; J Patterson; S M Brown; R Rampling Journal: Gene Ther Date: 2004-11 Impact factor: 5.250
Authors: M Enderlin; E V Kleinmann; S Struyf; C Buracchi; A Vecchi; R Kinscherf; F Kiessling; S Paschek; S Sozzani; J Rommelaere; J J Cornelis; J Van Damme; C Dinsart Journal: Cancer Gene Ther Date: 2008-08-01 Impact factor: 5.987
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: R A Morshed; M Gutova; J Juliano; M E Barish; A Hawkins-Daarud; D Oganesyan; K Vazgen; T Yang; A Annala; A U Ahmed; K S Aboody; K R Swanson; R A Moats; M S Lesniak Journal: Cancer Gene Ther Date: 2014-12-19 Impact factor: 5.987
Authors: Antonella Mangraviti; Stephany Yi Tzeng; Kristen Lynn Kozielski; Yuan Wang; Yike Jin; David Gullotti; Mariangela Pedone; Nitsa Buaron; Ann Liu; David R Wilson; Sarah K Hansen; Fausto J Rodriguez; Guo-Dong Gao; Francesco DiMeco; Henry Brem; Alessandro Olivi; Betty Tyler; Jordan J Green Journal: ACS Nano Date: 2015-02-10 Impact factor: 15.881
Authors: Timothy F Cloughesy; Joseph Landolfi; Michael A Vogelbaum; Derek Ostertag; James B Elder; Stephen Bloomfield; Bob Carter; Clark C Chen; Steven N Kalkanis; Santosh Kesari; Albert Lai; Ian Y Lee; Linda M Liau; Tom Mikkelsen; Phioanh Nghiemphu; David Piccioni; William Accomando; Oscar R Diago; Daniel J Hogan; Dawn Gammon; Noriyuki Kasahara; Thian Kheoh; Douglas J Jolly; Harry E Gruber; Asha Das; Tobias Walbert Journal: Neuro Oncol Date: 2018-09-03 Impact factor: 12.300